Get the Stockscreener App
2.805
2.09%
-0.065
Artiva Biotherapeutics Inc stock is traded at $2.805, with a volume of 30,993.
It is down -2.09% in the last 24 hours and up +77.85% over the past month.
Artiva Biotherapeutics Inc is a biopharmaceutical company. The company is engaged in advancing a pipeline of off-the-shelf, allogeneic NK cell therapies for the treatment of hematologic malignancies or solid tumors. The pipeline program of the company includes Artiva-Funded Trials and Collaborator-Funded Trials. The company pipeline includes AlloNK: is an allogeneic, off-the-shelf, cryopreserved NK cell therapy candidate designed to enhance the antibody-dependent cellular cytotoxicity (ADCC) effect of mAbs to drive B-cell. Others products includes: CAR-NK(AB201),CAR-NK(AB205).
See More
Previous Close:
$2.87
Open:
$2.79
24h Volume:
30,993
Relative Volume:
0.14
Market Cap:
$68.46M
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-
EPS:
-
Net Cash Flow:
-
1W Performance:
-6.33%
1M Performance:
+77.85%
6M Performance:
-28.13%
1Y Performance:
-75.13%
1-Day Range:
$2.74
$2.92
1-Week Range:
$2.74
$3.15
52-Week Range:
$1.47
$17.31
Artiva Biotherapeutics Inc Stock (ARTV) Company Profile
Name
Artiva Biotherapeutics Inc
Sector
Industry
Phone
(858) 267-4467
Address
5505 MOREHOUSE DRIVE, SAN DIEGO
Compare ARTV with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ARTV
Artiva Biotherapeutics Inc
|
2.81 | 75.04M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
384.39 | 96.11B | 11.42B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
560.63 | 60.40B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
430.23 | 54.91B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
671.14 | 41.30B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
294.82 | 33.25B | 3.81B | -644.79M | -669.77M | -6.24 |
Artiva Biotherapeutics Inc Stock (ARTV) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-11-25 | Resumed | H.C. Wainwright | Buy |
| Dec-30-24 | Initiated | H.C. Wainwright | Buy |
| Aug-13-24 | Initiated | Cantor Fitzgerald | Overweight |
| Aug-13-24 | Initiated | Jefferies | Buy |
| Aug-13-24 | Initiated | Needham | Buy |
| Aug-13-24 | Initiated | TD Cowen | Buy |
| Aug-13-24 | Initiated | Wedbush | Outperform |
View All
Artiva Biotherapeutics Inc Stock (ARTV) Latest News
Buy Rating Affirmed for Artiva Biotherapeutics Amid Promising AlloNK Data and Strong Financial Position - TipRanks
Is it time to cut losses on Artiva Biotherapeutics Inc.Secure Asset Flow and Trend Pattern Analysis - Newser
Published on: 2025-08-06 19:40:30 - Newser
Artiva Biotherapeutics: Navigating Earnings Disappointment While Building a Foundation for Long-Term Growth - AInvest
Artiva Biotherapeutics Reports Second Quarter 2025 Financial Results, Recent Business Highlights - GlobeNewswire
Artiva Biotherapeutics (ARTV) to Release Earnings on Thursday - Defense World
How Artiva Biotherapeutics Inc. stock performs during market volatilityAI Trend Detection for Entry Timing - Newser
Will Artiva Biotherapeutics Inc. benefit from macro trendsPredictable Income Summary for Long-Term Trades - Newser
Multi factor analysis applied to Artiva Biotherapeutics Inc.Chart Driven Entry Timing for Swing Trades - Newser
Artiva Biotherapeutics Inc. Stock Support and Resistance Levels You Should KnowSummary of Long-Term Buy Zone Stocks - Newser
Pattern recognition hints at Artiva Biotherapeutics Inc. upsideShort-Term Profit Alert With Entry Forecast - Newser
Applying Elliott Wave Theory to Artiva Biotherapeutics Inc.Deep Learning Stock Forecast for Investors - Newser
Artiva Biotherapeutics Inc.’s Price Action Aligns with Quant SignalsDaily Market Summary Analysis Strategy - beatles.ru
Published on: 2025-08-04 22:00:03 - Newser
How volatile is Artiva Biotherapeutics Inc. stock compared to the marketConsistent triple-digit returns - Jammu Links News
What makes Artiva Biotherapeutics Inc. stock price move sharplyGet real-time alerts on top-performing stocks - Jammu Links News
Is Artiva Biotherapeutics Inc. a good long term investmentBreakthrough financial growth - Jammu Links News
Is Artiva Biotherapeutics Inc. stock overhyped or has real potentialFree Reliable Investment Entry Point Signals - Newser
How does Artiva Biotherapeutics Inc. generate profit in a changing economyAchieve exceptional returns with expert guidance - Jammu Links News
Is it the right time to buy Artiva Biotherapeutics Inc. stockUnlock real-time stock alerts for quick profits - Jammu Links News
How does Artiva Biotherapeutics Inc. compare to its industry peersBuild wealth faster with consistent investment plans - Jammu Links News
Is Artiva Biotherapeutics Inc. stock overvalued or undervaluedHigh-yield investments - Jammu Links News
What catalysts could drive Artiva Biotherapeutics Inc. stock higher in 2025Breakthrough stock performance - Jammu Links News
What are analysts’ price targets for Artiva Biotherapeutics Inc. in the next 12 monthsUnlock rapid growth potential in your portfolio - Jammu Links News
Should I hold or sell Artiva Biotherapeutics Inc. stock in 2025Unlock exclusive trading strategies for gains - Jammu Links News
What are Artiva Biotherapeutics Inc. company’s key revenue driversFree Capital Efficiency Planning - Jammu Links News
What drives Artiva Biotherapeutics Inc. stock priceOverwhelming financial success - Jammu Links News
Leading vs lagging indicators on Artiva Biotherapeutics Inc. performanceFree Technical Stock Breakout Predictions - Newser
Options Data Show Bullish Bias in Artiva Biotherapeutics Inc.Secure Capital Picks With Upside Potential Tracked - metal.it
Technical analysis overview for Artiva Biotherapeutics Inc. stockBuy Candidate Summary Based on Fundamentals - Newser
Is Artiva Biotherapeutics Inc. a growth stock or a value stockLow Risk Picks With Proven Results - jammulinksnews.com
Technical signs of recovery in Artiva Biotherapeutics IncFree Top Gaining Picks With Entry Signals - Newser
Is now a turning point for Artiva Biotherapeutics Inc.Asset Growth Pattern and Return Summary - Newser
Does Artiva Biotherapeutics Inc. qualify in momentum factor screeningYield Curve Outlook and Long-Term Implication Summary - Newser
Artiva Biotherapeutics shares rise 6.19% intraday after VYNE Therapeutics' Phase 2b trial results. - AInvest
Artiva Biotherapeutics Inc Stock (ARTV) Financials Data
There is no financial data for Artiva Biotherapeutics Inc (ARTV). Check out other stocks for more information.
Revenue
Net Income
Cash Flow
EPS
0.36%
1.76%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):